IGF2 and systemic sclerosis: Based on our recent characterization of NL and SSc lung fibroblast transcriptomic signatures [26,27], we identified novel targets downstream of IGF-II that include collagen type III (COL3A1), several collagen posttranslational modification enzymes, and collagen degradation enzymes.